Cancer Therapy
Lipidemic profile of women treated with adjuvant exemestane therapy not significantly altered
Published in Women's Health Weekly, November 10th, 2005
"Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease," investigators in Greece reported.
"In a companion subprotocol to the ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied) trial," C. Markopoulos and colleagues "compared the effect of the steroidal aromatase inactivator exemestane on the lipid profile of post-menopausal women with operable breast...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Cancer Risk Factors
Parental consanguinity in Arabs not associated with higher risk of breast cancer - HIV/AIDS Transmission
Planned caesarian section is safe and effective for preventing transmission of HIV - Menopause
Testosterone therapy improves sexual function in post-menopausal women - Ovarian Cancer
Twelve cohort studies indicate risk of ovarian cancer not linked to fruit and vegetable diet - Type 2 Diabetes
Visceral adipose tissue and type 2 diabetes highest among Filipino women - Alcohol Use
Prenatal exposure to alcohol may cause visual problems in infants - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
